CoreValve® transcatheter self-expandable aortic bioprosthesis

Giuseppe Bruschi, Federico De Marco, Luigi Martinelli, Silvio Klugmann

Research output: Contribution to journalArticlepeer-review


Transcatheter aortic valve implantation has been designed to treat patients affected by severe symptomatic aortic stenosis considered extremely high risk for surgical aortic valve replacement. The CoreValve® (Medtronic Inc., MN, USA) is a multilevel self-expanding and fully radiopaque nitinol frame with a diamond cell configuration that holds a trileaflet porcine pericardial tissue valve and anchors the device in the native anatomy. CoreValve was the first percutaneous valve to be granted the CE mark for transfemoral implantation in May 2007 and the CoreValve US Pivotal Trial is actively underway. The CoreValve is available in four sizes (23, 26, 29 and 31 mm) to serve a broad range of patients' annulus from 18 to 29 mm. All the valves fit into an 18-Fr size catheter. Currently, more than 35,000 patients have been treated in more than 60 countries worldwide from the femoral artery, the axillary artery and, more recently, from a direct aortic approach, with excellent results up to 4-year follow-up.

Original languageEnglish
Pages (from-to)15-26
Number of pages12
JournalExpert Review of Medical Devices
Issue number1
Publication statusPublished - Jan 2013


  • aortic stenosis
  • catheter-based valve intervention
  • CoreValve®
  • structural heart disease
  • transcatheter technique

ASJC Scopus subject areas

  • Surgery
  • Biomedical Engineering


Dive into the research topics of 'CoreValve® transcatheter self-expandable aortic bioprosthesis'. Together they form a unique fingerprint.

Cite this